Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose IV fosaprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy
2012-001718-41Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Merck & Co. Primary endpoint: Complete response in delayed phase. Started May 2012; status: completed.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2012-001718-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001718-41.